Dr. Kerr on Misconceptions With Molecular Profiling in Lung Cancer
Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.
Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung Cancer
Dr. Keith Keer on PD-L1 in Lung Cancer
Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
2 Clarke Drive Cranbury, NJ 08512